TWD 179.0
(-1.65%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | 334.7 Million TWD | -55.7% |
2022 | 748.45 Million TWD | 75.79% |
2021 | 425.76 Million TWD | 229.48% |
2020 | 129.22 Million TWD | -49.4% |
2019 | 255.37 Million TWD | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 Q2 | 185.11 Million TWD | -0.82% |
2024 Q1 | 204.84 Million TWD | 143.95% |
2023 Q4 | 83.96 Million TWD | -31.56% |
2023 FY | 331.54 Million TWD | -55.7% |
2023 Q3 | 122.68 Million TWD | 34.42% |
2023 Q2 | 91.27 Million TWD | 171.52% |
2023 Q1 | 33.61 Million TWD | -78.19% |
2022 FY | 748.45 Million TWD | 75.79% |
2022 Q4 | 154.09 Million TWD | 0.0% |
2021 FY | 425.76 Million TWD | 229.48% |
2020 FY | 129.22 Million TWD | -49.4% |
2019 FY | 255.37 Million TWD | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
Nang Kuang Pharmaceutical Co., Ltd. | 259.91 Million TWD | -28.778% |
Maxigen Biotech Inc. | 149.85 Million TWD | -123.361% |
SciVision Biotech Inc. | 199.63 Million TWD | -67.657% |
Bionime Corporation | -13.33 Million TWD | 2609.236% |
Pegavision Corporation | 1.98 Billion TWD | 83.105% |